How obesity-related inflammation affects treatment response in rheumatoid arthritis patients
Official title: Obesity-Induced Inflammatory Mediators Predict Lack of Response in Patients with Rheumatoid Arthritis Starting Biological Therapies
Funded at University of California, San Diego · NIH-10781543 · Data updated 2026-11-12
This study is looking at how certain substances linked to obesity can help doctors figure out which rheumatoid arthritis treatments will work best for you, so they can personalize your care and improve your results.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $506,085 |
| NIH project number | 1R01AR083584-01 |
| Project ID | NIH-10781543 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with rheumatoid arthritis who are starting biological therapies and have varying levels of obesity.
✕Less likely to help
Patients with rheumatoid arthritis who are not starting biological therapies or those without obesity-related inflammatory issues may not benefit from this research.
What this research studies
This research investigates how inflammatory mediators related to obesity can predict the effectiveness of biological therapies in patients with rheumatoid arthritis (RA). The study aims to identify specific biomarkers that can help personalize treatment by determining which patients are likely to respond well to certain therapies. By analyzing a combination of proteins and lipids associated with obesity, researchers hope to uncover patterns that correlate with treatment outcomes. This approach seeks to improve the management of RA by tailoring therapies to individual patient profiles.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment strategies for patients with rheumatoid arthritis, improving their overall health outcomes.
How similar studies have gone: Previous studies have shown promise in identifying biomarkers for treatment response in rheumatoid arthritis, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of California, San Diego
La Jolla, United States Active
Researchers
- Principal investigator: Guma, Monica — University of California, San Diego
- Study coordinator: Guma, Monica
Related research
Other NIH-funded projects on the same topics.
-
Obesity-related inflammatory signals predicting treatment response in rheumatoid arthritis patients starting biologics
This study looks at whether inflammatory markers tied to obesity can predict which RA patients will respond poorly to new biologic therapies.
-
How obesity-related inflammation affects biologic treatment for rheumatoid arthritis
This work looks at whether obesity-linked proteins and lipids explain why some people with rheumatoid arthritis don't improve after starting biologic medicines.
-
Gut microbes and methotrexate: boosting RA treatment through microbiome targets
Researchers are studying how gut bacteria affect how well methotrexate works for people with rheumatoid arthritis, aiming to make MTX effective for more patients.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
-
Role of Stabilin receptors in rheumatoid arthritis
A short study to understand how certain scavenger receptors may influence the development and progression of rheumatoid arthritis in adults.
-
IgG glycosylation and endothelial FcγRIIB: understanding RA-related heart and blood vessel disease
This project looks at how rheumatoid arthritis affects blood vessels and clotting, with the goal of uncovering new ways to prevent heart and stroke risk for people with RA.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.